Arvinas: FDA Approval Validates The Platform, But Does Not Signal Near-Term Profitability
2026-05-12 13:31:40 ET
On May 1st , the FDA approved Veppanu (vepdegestrant), a novel small molecule degrader of the estrogen receptor (ER) to treat ER+/HER2- breast cancer for relapsed patients with ESR1 mutations. This is an important scientific milestone, the first FDA-approved Preteolysis Targeting Chimera (PROTAC). A PROTAC drug is based on Nobel Prize winning science in ubiquitin-mediated protein degradation. In short, PROTAC drugs bind a target of interest, tagging it for destruction by this natural pathway. The offending protein is degraded by the ubiquitin-proteasome system resulting in destruction, rather than simple inhibition that is achieved by most small molecule drugs. Arvinas ( ARVN ) together with its partner Pfizer ( PFE ) have deep expertise in the field, with Arvinas' founder Craig Crews a renowned and pioneering research professor at Yale University....
Read the full article on Seeking Alpha
For further details see:
Arvinas: FDA Approval Validates The Platform, But Does Not Signal Near-Term Profitability
NASDAQ: NVS
NVS Trading
-0.26% G/L:
$150.47 Last:
852,043 Volume:
$151.84 Open:
